What does this research mean for the field?

GLP-1 receptor agonists increase the risk of cholelithiasis and gastroesophageal reflux disease (GERD) compared to placebo, but do not increase the risk of other gastrointestinal or biliary adverse events. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

January 1, 2026Annals of Internal Medicine1 citations

View Full Paper

GLP-1RAs increase risk for cholelithiasis and GERD but not other GI or biliary adverse events vs. placebo

KAKelsey L. AndersonBeth Israel Deaconess Medical Center JFJoseph D. FeuersteinBeth Israel Deaconess Medical Center

Key Points

Key points are not available for this paper at this time.

Abstract

CLINICAL IMPACT RATINGS: GIM/FP/GP: Formula: see text Endocrinology: Formula: see text Gastroenterology: Formula: see text.

问 AI

Bookmark

View Full Paper

问 AI

Bookmark

View Full Paper

GLP-1RAs increase risk for cholelithiasis and GERD but not other GI or biliary adverse events vs. placebo

Key Points

Abstract

Cite This Study

Also Consider

Also Consider